IN2014DN00078A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00078A
IN2014DN00078A IN78DEN2014A IN2014DN00078A IN 2014DN00078 A IN2014DN00078 A IN 2014DN00078A IN 78DEN2014 A IN78DEN2014 A IN 78DEN2014A IN 2014DN00078 A IN2014DN00078 A IN 2014DN00078A
Authority
IN
India
Prior art keywords
composition
oligodeoxynucleotide
cpg
allergies
adjuvants
Prior art date
Application number
Inventor
Eric Tartour
Ludger Johannes
Original Assignee
Inst Curie
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Centre Nat Rech Scient, Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris, Univ Paris Descartes filed Critical Inst Curie
Publication of IN2014DN00078A publication Critical patent/IN2014DN00078A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG like oligodeoxynucleotide. This composition can used to treat cancers infectious diseases caused by bacterial viral fungal parasitic or protozoan infections allergies and/or autoimmune diseases.
IN78DEN2014 2011-07-22 2012-07-23 IN2014DN00078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305959A EP2548571A1 (en) 2011-07-22 2011-07-22 Compositions having means for targeting at least one antigen to dendritic cells
PCT/EP2012/064425 WO2013014128A1 (en) 2011-07-22 2012-07-23 Compositions having means for targeting at least one antigen to dendritic cells

Publications (1)

Publication Number Publication Date
IN2014DN00078A true IN2014DN00078A (en) 2015-05-15

Family

ID=46548478

Family Applications (1)

Application Number Title Priority Date Filing Date
IN78DEN2014 IN2014DN00078A (en) 2011-07-22 2012-07-23

Country Status (9)

Country Link
US (2) US20140199379A1 (en)
EP (2) EP2548571A1 (en)
JP (1) JP2014523918A (en)
CN (1) CN103796674A (en)
AU (1) AU2012288949B2 (en)
CA (1) CA2841036A1 (en)
IL (1) IL230525A0 (en)
IN (1) IN2014DN00078A (en)
WO (1) WO2013014128A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204762A1 (en) * 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
JP6697384B2 (en) 2013-07-25 2020-05-20 イグジキュア, インコーポレーテッドExicure, Inc. Spherical nucleic acid-based constructs as immunostimulants for prophylactic and therapeutic use
TR201908550T4 (en) 2014-06-04 2019-07-22 Exicure Inc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications.
CN104277094A (en) * 2014-07-04 2015-01-14 文康医疗技术（深圳）有限公司 DC (Dendritic Cell) targeting peptide and application of targeting peptide
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN107206061A (en) * 2015-05-22 2017-09-26 布莱恩·J·赫尔尼奇 The preparation of multiple dose injection dendritic cell vaccine, therapeutic alliance and estrogen receptor positive HER2 breast cancer treatments for blocking HER2 and HER3
JP6534146B2 (en) * 2015-06-10 2019-06-26 国立大学法人 東京大学 Adjuvant for vaccine, vaccine, and method for inducing immunity
WO2017117269A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
US20210100897A1 (en) * 2017-05-03 2021-04-08 Agency For Science, Technology And Research Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof
WO2023070317A1 (en) * 2021-10-26 2023-05-04 江苏省农业科学院 Bifunctional nanobody based on dc, and construction method therefor and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766193B1 (en) 1997-07-18 2001-09-14 Inst Curie CHEMICAL POLYPEPTIDE COMPRISING FRAGMENT B OF TOXIN SHIGA AND PEPTIDES OF THERAPEUTIC INTEREST
EP1229045A1 (en) 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
GB0524409D0 (en) 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines

Also Published As

Publication number Publication date
AU2012288949A1 (en) 2013-04-11
JP2014523918A (en) 2014-09-18
IL230525A0 (en) 2014-03-31
AU2012288949B2 (en) 2014-05-01
EP2548571A1 (en) 2013-01-23
EP2734225A1 (en) 2014-05-28
US20140199379A1 (en) 2014-07-17
CN103796674A (en) 2014-05-14
WO2013014128A1 (en) 2013-01-31
CA2841036A1 (en) 2013-01-31
US20170042994A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
IN2014DN00078A (en)
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
EP2563366A4 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
ZA201301013B (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
MX2021003018A (en) Tec family kinase inhibitor adjuvant therapy.
IN2014CN04251A (en)
EA201291157A1 (en) MULTIVALENT VACCINES WITH SYNTHETIC NANOSATORS
GB2518813A (en) OMV vaccine against Burkholderia infections
UY34411A (en) IMMUNO LINKERS AGAINST SCLEROSTINE
IN2014DN08812A (en)
UY34409A (en) IMMUNO LINKERS AGAINST TNF
MX2013010286A (en) Amatoxin-conjugates with improved linkages.
HK1200491A1 (en) Methods and compositions for regulating hiv infection hiv
MX2013003153A (en) Substituted nucleotide analogs.
UY34582A (en) ANTI-CXCR3 ANTIBODIES
GB201106750D0 (en) Novel compounds
EA201300585A1 (en) Immunomodulatory Oligonucleotides
NZ603527A (en) Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
ZA201309386B (en) Vaccine composition comprising an inactivated chikungunya virus strain
CA2798214C (en) Vaccine against beta-herpesvirus infection and use thereof
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
HK1201175A1 (en) Antigen presenting cancer vaccine with gamma interferon
UY34286A (en) IMPROVED VACCINE DIAGNOSIS
IN2014DN08407A (en)